Fagron strengthens its leadership with the acquisition of Guinama in Spain
Acquiring Company
Fagron
Acquired Company
Guinama
Description
Fagron solidifies its leadership position by acquiring Guinama in Spain, a move that underscores Fagron’s commitment to expanding across key markets and strengthening its market positioning in the Iberian pharmaceutical compounding market. The acquisition will enhance Fagron’s capabilities and competitive position, further solidifying its leading role within the sector and country.
Quick answer
Fagron is acquiring Guinama, announced February 4, 2025. Fagron is based in Rotterdam, South Holland, Netherlands.
- How much did Fagron pay for Guinama?
- The deal value was not disclosed.
- What does Fagron do?
- Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics and patients in more than 30 countries around the world.
- Where are Fagron and Guinama based?
- Fagron is based in Rotterdam, South Holland, Netherlands. Guinama is based in Valencia, Valencian Community, Spain.
- Who are the decision-makers at Fagron?
- Fundz holds 2 contacts at Fagron. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- GSK completes acquisition of IDRx, Inc. to enhance precision therapeutics for treating gastrointestinal stromal tumours (February 24, 2025)
- Eton Pharmaceuticals completes acquisition of Galzin® (zinc acetate) from Teva Pharmaceuticals USA, Inc. to advance treatment for Wilson Disease (January 5, 2025)
- Cycle Pharmaceuticals completes acquisition of Banner Life Sciences, LLC to expand MS product portfolio (January 13, 2025)
- Azurity Pharmaceuticals acquires Covis Pharma (March 14, 2025)
- Pan-Am Dental completes strategic acquisitions of JB Dental Lab and Avaneer Dental Studio, solidifying its position as a top 10 dental lab group (February 10, 2025)
- AbbVie completes acquisition of Nimble Therapeutics to expand its immunology pipeline (January 23, 2025)
Who to call at Fagron, and when
When Fagron changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Fagron raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Fagron, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Fagron. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Fagron makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Guinama?
Guinama was acquired by Fagron, based in Rotterdam. The deal was reported on February 4, 2025. Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics and patients in more than 30 countries around the world. Fagron is privately held and operates in Biotechnology.
When did Fagron acquire Guinama?
Fagron's acquisition of Guinama was reported on February 4, 2025. Fagron solidifies its leadership position by acquiring Guinama in Spain, a move that underscores Fagron’s commitment to expanding across key markets and strengthening its market positioning in the Iberian pharmaceutical compounding market. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Guinama do?
Guinama, based in Valencia, Spain, specializes in repackaging and distribution of active pharmaceutical ingredients and excipients to pharmacies, hospitals and industries. It is privately held, operating in Manufacturing, and is based in Valencia.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.